Google Translate Disclaimer

A number of pages on the Government of Saskatchewan's website have been professionally translated in French. These translations are identified by a yellow box in the right or left rail that resembles the link below. The home page for French-language content on this site can be found at:

Renseignements en Français

Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.

Software-based translations do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language. The Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos and other file formats such as portable document formats (PDFs).

Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.

Stick it to COVID: Expanding Treatment Options

Released on January 18, 2022

On January 17, Health Canada approved the use of Paxlovid, a new antiviral drug made by Pfizer.  This is the first Health Canada-approved oral antiviral (pill) for COVID-19, recommended for people who test positive and are at high risk of severe outcomes including hospitalization or death.

Paxlovid is taken twice a day for five days by those with COVID-19.  It stops the virus from multiplying, to help people overcome the infection and potentially recover faster.

Saskatchewan expects to receive a shipment of Paxlovid this week.  Quantities are expected to be limited at first and will increase throughout the year.  Details on eligibility criteria and how to access this medication will be provided in the coming days.

Update to Monoclonal Antibody Treatment Eligibility

Saskatchewan offers monoclonal antibody treatment for eligible residents who have received a positive test result on either a rapid antigen test or a PCR test as a tool to help prevent serious COVID-19 outcomes.

You are eligible if you have a positive test result and:

  • Have not been vaccinated or are immunocompromised regardless of vaccination status; AND
  • Are within seven days of becoming symptomatic; AND
  • Are 55 years or older or 18 years and older with specific high-risk co-morbidity.

Previously, the requirement had been within five days of becoming symptomatic.

If you meet these requirements, you may be referred for treatment.  Call HealthLine 811 or 306-766-6388 between 8 a.m. and 4 p.m., seven days a week to speak with a clinician regarding monoclonal antibodies.

Treatment is No Substitute for Vaccination

While Saskatchewan supports new treatments for those most at risk for severe COVID-19 illnesses, vaccination remains the best tool available to prevent hospitalizations and death due to COVID-19.  Immunization does not offer absolute protection against COVID-19 but improves your body's defense against the virus.  It is safe and effective.

All Saskatchewan residents age five and older are eligible to be fully vaccinated, and residents age eighteen and older are eligible for third/booster doses. Certain at-risk populations are now also eligible for fourth doses.  For more information on the third/booster dose eligibility, see

There are more than 30,000 COVID-19 immunization appointments available through the Saskatchewan Health Authority clinics in addition to those offered by pharmacies throughout the province.  Stick it to COVID and book your immunization today.

COVID-19 Summary for January 18, 2022:

  • From January 12 - January 18, 15,309 first and second doses of COVID-19 vaccine have been given in Saskatchewan, bringing the total number of primary series vaccines administered in the province to 1,834,160. 
  • An additional 42,538 third and fourth doses have been administered in the province from January 12 - January 18, bringing the total number of vaccines including boosters administered in the province to 2,251,572.  Forty-four per cent of eligible residents age 18+ have now received their booster dose.
  • As of January 18, 88 per cent of residents 12 years and older and 85 per cent of residents five years older have received their first dose.  Eighty-four per cent of residents 12 years and older and 78 per cent of residents five years and older are fully vaccinated.
  • There were 8,533 new cases of COVID-19 to report in Saskatchewan from January 12 - January 18, bringing the provincial total to 102,641 cases.  There were 5,670 recoveries recorded during the same period.
  • The seven-day average of new COVID-19 cases in Saskatchewan is currently 1,219 (101.2/100,000).
  • Zero new deaths were reported January 12 - January 18.
  • There were 452 new lineage results reported for January 12 - January 18. 
  • As of January 18, 189 individuals are hospitalized including 171 inpatient hospitalizations and 18 ICU hospitalizations. Of the 189 patients, 67 (35.4 per cent) were not fully vaccinated.
  • Since October 25, 57 monoclonal antibody infusion treatments have been delivered.
  • From January 12 - January 18, there were 25,804 COVID-19 tests processed in Saskatchewan.


For more information, contact:

Phone: 306-787-4083

We need your feedback to improve Help us improve